A 48+ year lady had modified radical mastectomy. Pathologically it was T2 tumour (2cms+) . Histologically , moderately well-differentiated infiltrating ductal carcinoma. Gland status unknown. Histopathology also revealed associated abnormal ductal hyperplasia.
She lives in a remote developing country. She has access to chemotherapy. Hormone receptor status not available ( not done in the country and has no access either). Will you recommend her to take Tamoxifen, based on evidences so far available. Is the presence of abnormal ductal hyperplasia in the operative specimen, influence your decision for adjuvant Tamoxifen therapy; either way?
